|
Hypertensive disease
|
0.580 |
GeneticVariation
|
group |
BEFREE |
Ser89Asn (S89N) polymorphisms of the UTS2 gene were associated with hypertension in a Chinese female population.
|
27941008 |
2017 |
|
Hypertensive disease
|
0.580 |
Biomarker
|
group |
BEFREE |
Urotensin II and its receptor are thought to be involved in various cardiovascular diseases such as heart failure, pulmonary hypertension and atherosclerosis.
|
28163023 |
2017 |
|
Hypertensive disease
|
0.580 |
Biomarker
|
group |
BEFREE |
Intracerebroventricular (ICV) injection of UII in these vertebrates provokes hypertension and tachycardia, suggesting that the cardio-inhibitory baroreflex response is impaired.
|
28239335 |
2017 |
|
Hypertensive disease
|
0.580 |
AlteredExpression
|
group |
BEFREE |
Chronic treatment with nimesulide or NS-398 (5 mg/kg/day) for 3 weeks lowered high blood pressure and cardiac hypertrophy with decreased expression levels of cardiac hypertrophy markers [atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP)], Ang type 1 receptor, urotensin II, and urotensin II receptor in 2K1C rats.
|
25846103 |
2015 |
|
Hypertensive disease
|
0.580 |
Biomarker
|
group |
BEFREE |
The involvement of urotensin II, a vasoactive peptide acting via the G protein-coupled urotensin II receptor, in arterial hypertension remains contentious.
|
19001524 |
2009 |
|
Hypertensive disease
|
0.580 |
Biomarker
|
group |
BEFREE |
Iontophoresis of U-II in healthy volunteers produces vasodilation (of the forearm) while in patients with heart failure or hypertension a constriction is observed.
|
17680191 |
2007 |
|
Hypertensive disease
|
0.580 |
GeneticVariation
|
group |
BEFREE |
We studied single nucleotide polymorphisms (SNPs) and haplotypes in the urotensin-II (UTS2) and urotensin-II receptor gene (UTS2R) in Hong Kong Chinese (224 hypertensive and 306 normotensive unrelated subjects) and their relation to hypertension and the metabolic syndrome.
|
16597476 |
2006 |
|
Hypertensive disease
|
0.580 |
Biomarker
|
group |
CTD_human |
Urotensin-II (U-II) receptors are widely distributed in the central nervous system.Intracerebroventricular (i.c.v.) injection of U-II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion.
|
16160878 |
2005 |
|
Hypertensive disease
|
0.580 |
Biomarker
|
group |
LHGDN |
Our findings raise the possibility that urotensin II may have an aetiological role in hypertension and its complications.
|
15201550 |
2004 |
|
Hypertensive disease
|
0.580 |
Biomarker
|
group |
RGD |
These results suggest that central urotensin II may play a role in the pathogenesis of hypertension in SHR.
|
14621188 |
2003 |
|
Appetite Disorders
|
0.300 |
Biomarker
|
group |
CTD_human |
Behavioral effects of urotensin-II centrally administered in mice.
|
16160878 |
2005 |
|
Eating Disorders
|
0.300 |
Biomarker
|
group |
CTD_human |
Behavioral effects of urotensin-II centrally administered in mice.
|
16160878 |
2005 |
|
Movement Disorders
|
0.300 |
Biomarker
|
group |
CTD_human |
Behavioral effects of urotensin-II centrally administered in mice.
|
16160878 |
2005 |
|
Water Intoxication
|
0.300 |
Biomarker
|
disease |
CTD_human |
Behavioral effects of urotensin-II centrally administered in mice.
|
16160878 |
2005 |
|
Etat Marbre
|
0.300 |
Biomarker
|
disease |
CTD_human |
Behavioral effects of urotensin-II centrally administered in mice.
|
16160878 |
2005 |
|
Bradycardia
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Urotensin-II (U-II) receptors are widely distributed in the central nervous system.Intracerebroventricular (i.c.v.) injection of U-II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion.
|
16160878 |
2005 |
|
Feeding Disorders
|
0.300 |
Biomarker
|
disease |
CTD_human |
Behavioral effects of urotensin-II centrally administered in mice.
|
16160878 |
2005 |
|
Feeding and Eating Disorders
|
0.300 |
Biomarker
|
group |
CTD_human |
Behavioral effects of urotensin-II centrally administered in mice.
|
16160878 |
2005 |
|
Diabetic Nephropathy
|
0.220 |
Biomarker
|
disease |
BEFREE |
Urotensin II (UII) and autophagy have been considered as important components in the pathogenesis of diabetic nephropathy.
|
27459313 |
2017 |
|
Myocardial Infarction
|
0.220 |
GeneticVariation
|
disease |
BEFREE |
Subsequent multivariable logistic regression analysis with adjustment for covariates revealed that the G-->A (Ser89Asn) polymorphism of UTS2 [odds ratio (OR), 1.90; 95% confidence interval (CI), 1.18-3.08], the 2445G-->A (Ala54Thr) polymorphism of FABP2 (OR, 1.72; 95% CI, 1.23-2.40), the -11377C-->G polymorphism of ADIPOQ (OR, 1.43; 95% CI, 1.15-1.79), the -231A-->G polymorphism of EDNRA (OR, 0.65; 95% CI, 0.48-0.89), and the -108/3G-->4G polymorphism of PDX1 (OR, 0.64; 95% CI, 0.48-0.87) were significantly (P<0.05) associated with MI.
|
19361803 |
2009 |
|
Diabetic Nephropathy
|
0.220 |
Biomarker
|
disease |
RGD |
Diabetes-induced upregulation of urotensin II and its receptor plays an important role in TGF-beta1-mediated renal fibrosis and dysfunction.
|
18796544 |
2008 |
|
Myocardial Infarction
|
0.220 |
GeneticVariation
|
disease |
BEFREE |
In patients with acute cardiac ischemia, circulating urotensin II is lower than normal and low plasma urotensin II signals a higher risk of adverse clinical events following myocardial infarction.
|
18277155 |
2008 |
|
Diabetic Nephropathy
|
0.220 |
AlteredExpression
|
disease |
BEFREE |
In the context of its known biological actions, the dramatic overexpression of UII and its receptor implicate this vasoactive peptide as a possible novel factor in the pathogenesis of diabetic nephropathy.
|
15492948 |
2004 |
|
Myocardial Infarction
|
0.220 |
Biomarker
|
disease |
RGD |
Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators.
|
15549273 |
2004 |
|
Asthma
|
0.210 |
AlteredExpression
|
disease |
BEFREE |
We found that both UII and TGF-β1 were upregulated in asthma lung tissues.
|
22270542 |
2012 |